Navigation Links
First Patients Enrolled in the Access-Europe Study of The MitraClip(R) Therapy
Date:4/6/2009

European Post Market Observational Study Intended to Collect Data to Demonstrate the Clinical and Health Economic Benefits of the MitraClip(R) Therapy for Patients with Mitral Regurgitation

MENLO PARK, Calif., April 6 /PRNewswire/ -- Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, announced today the first enrollment in the ACCESS-Europe study, a post-market observational study of the MitraClip(R) therapy in Europe. The MitraClip(R) system is the first commercially available treatment option for non-surgical mitral valve repair for patients suffering from the effects of functional and degenerative mitral regurgitation (MR).

MR affects millions of people worldwide and is the most common type of heart valve insufficiency in Europe and the United States. In Europe, similar to the US, there are approximately 250,000 new diagnoses of significant MR each year; however, only 20 percent or approximately 50,000 of these patients undergo surgery each year. Non-surgical patients and many of the higher risk surgical patients continue to be affected by the chronic volume overload caused by MR, which requires the heart to work harder, which may lead to heart failure and hospitalization.

The first patients were enrolled in ACCESS-Europe by a team led by Professor Corrado Tamburino, M.D.; Gian Paolo Ussia, M.D.; Salvatore Scandura, M.D.; and Sarah Mangiafico, M.D. at Ferrarotto Hospital at Catania University in Sicily, Italy.

"ACCESS-Europe will provide important clinical care and health economic information about the MitraClip(R) therapy," said Professor Tamburino, chair of cardiology, cardiology department, cardiac catheterization and interventional cardiology, Ferrarotto Hospital, University of Catania, Sicily. "This data will allow us to further understand the benefits of the MitraClip(R) therapy for patients with mitral regurgitation and the health economic benefits of a less invasive alternative for patients suffering from MR."

The ACCESS-Europe study will evaluate the MitraClip(R) therapy in the continuum of care available to patients with MR. Patients will be evaluated at baseline through 12 months after enrollment. As many as 20 institutions within Europe will participate and up to 300 patients treated with the MitraClip(R) device will be enrolled. In addition, information will be collected in two comparator groups, one which includes medically managed heart failure patients with MR and another which includes patients who are undergoing mitral valve surgery for MR.

"Initiating enrollment in ACCESS-Europe is another important milestone for Evalve and the MitraClip therapy," said Ferolyn Powell, president and chief executive officer of Evalve. "This study is designed to provide meaningful clinical and health economic information building on the important foundation of data already generated in the US. The early experience in Europe has been primarily the treatment of patients who are either non-surgical candidates, or higher risk surgical patients, with functional MR."

Evalve received CE Mark approval for the MitraClip(R) system last year, and has worked with hospitals across Europe to establish training programs in support of the European roll out. Patients have been treated in Italy, Germany, the United Kingdom, the Netherlands and Switzerland.

About the MitraClip(R) Procedure

Percutaneous mitral repair with Evalve's MitraClip(R) device is performed by physicians in the catheterization laboratory. The heart beats normally during the procedure, and therefore does not require a heart-lung bypass machine. In addition to improving blood flow through the heart, the procedure may also relieve symptoms such as fatigue and shortness of breath that often affect patients with significant MR. After treatment, patients generally recover quickly. The MitraClip(R) device may improve quality of life and may help MR patients avoid or delay surgery, having preserved surgical options (valve repair or replacement) should surgery become necessary.

About Evalve, Inc.

Founded in 1999, Evalve, Inc., headquartered in Menlo Park, Calif., has developed a proprietary system which enables percutaneous repair of cardiac valves. The company's initial products are intended to reduce the risks, trauma and costs associated with current open, arrested heart surgical options. For more information about Evalve, Inc., and for an animated explanation of the procedure using the MitraClip(R) device, visit www.evalveinc.com. Evalve is the first portfolio company from the medical device company incubator, The Foundry (www.thefoundry.com).

The MitraClip(R) system is currently undergoing clinical evaluation in the United States and Canada. The MitraClip(R) system is available for commercial distribution in the European Union.

MitraClip(R) and Evalve are registered trademarks of Evalve, Inc.


'/>"/>
SOURCE Evalve, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Social Security Administration First to Go Live With CONNECT Solution for Nationwide Health Information Network
2. Video: New First Response(R) Fertility Test Helps Women Answer the Question: Am I Able to Get Pregnant?
3. Imagine No More Waits for Emergency Room Care ... InQuickER Chooses Trevelino/Keller Communications to Launch First Service of Its Kind
4. I-Therapeutix Announces First Commercial Use of I-ZIP(R) Adherent Ocular Bandage for Clear Corneal Cataract Incisions
5. First Patients Treated in India Using CyberKnife Radiosurgery
6. Zimmer Holdings Announces Live Audio Webcast and Conference Call of First Quarter 2009 Results
7. World-first high blood pressure treatment trialled in Melbourne
8. Covance Inc. Invites You to Join the Webcast of Its First Quarter 2009 Financial Results Conference Call
9. Berlin Heart Receives First Regulatory Approval in North America
10. NIH releases the first research plan to reduce the burden of digestive diseases
11. LodgeNet Healthcare Provides Industrys First Integrated High-Definition Interactive System for Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/26/2016)... 2016 Story Highlights: ... within the health care industry is causing providers to ... , Deloitte offers a suite of solutions for health ... efficient cost optimization: labor resource analysis, revenue cycle optimization ... better outcomes and better economics ...
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
Breaking Medicine Technology: